Original Article

Attributable mortality of vancomycin resistance in ampicillin-resistant Enterococcus faecium bacteremia in Denmark and the Netherlands: A matched cohort study

Wouter C. Rottier MD, PhD, Mette Pinholt MD, PhD, Akke K. van der Bij MD, PhD, Magnus Arpi MD, Sybrandus N. Blank MD, Marijgie H. Nabuurs-Franssen MD, PhD, Gijs J.H.M. Ruijs MD, PhD, Matthijs Tersmette MD, PhD, Jacobus M. Ossewaarde MD, PhD, Rolf H. Groenwold MD, PhD, Henrik Westh MD, PhD, Marc J.M. Bonten MD, PhD, for the Dutch VRE Bacteremia Investigators and the Danish Collaborative Bacteremia Network (DACOBAN)

Abstract

Objective: To study whether replacement of nosocomial ampicillin-resistant Enterococcus faecium (ARE) clones by vancomycin-resistant Enterococcus faecium (VRE) bacteria, and to evaluate whether any such increase is mediated by a delay in appropriate antibiotic therapy.

Design: Retrospective, matched-cohort study.

Setting: The study included 20 Dutch and Danish hospitals from 2009 to 2014.

Patients: Within the study period, 63 patients with VRE bacteremia (36 Dutch and 27 Danish) were identified and subsequently matched to 234 patients with ARE bacteremia (130 Dutch and 104 Danish) for hospital, ward, length of hospital stay prior to bacteremia, and age. For all patients, 30-day mortality after bacteremia onset was assessed.

Methods: The risk ratio (RR) reflecting the impact of vancomycin resistance on 30-day mortality was estimated using Cox regression with further analytic control for confounding factors.

Results: The 30-day mortality rates were 27% and 38% for ARE in the Netherlands and Denmark, respectively, and the 30-day mortality rates were 33% and 48% for VRE in these respective countries. The adjusted RR for 30-day mortality for VRE was 1.54 (95% confidence interval, 1.06–2.25). Although appropriate antibiotic therapy was initiated later for VRE than for ARE bacteremia, further analysis did not reveal mediation of the increased mortality risk.

Conclusions: Compared to ARE bacteremia, VRE bacteremia was associated with higher 30-day mortality. One explanation for this association would be increased virulence of VRE, although both phenotypes belong to the same well-characterized core genomic lineage. Alternatively, it may be the result of unmeasured confounding.

doi: 10.1017/ice.2021.216

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the Netherlands and Denmark, ampicillin-resistant, vancomycin-susceptible \textit{E. faecium} (ARE) has been the dominant hospital phenotype of \textit{Enterococcus faecium} for years, stably contributing to >80% of all invasive \textit{E. faecium} isolates.\textsuperscript{1,2} As elsewhere, these countries are faced with increased polyclonal hospital outbreaks of \textit{E. faecium} with combined resistance to ampicillin and vancomycin (VRE).\textsuperscript{3,4} VRE presumably originated directly from the omnipresent ARE through acquisition of \textit{vanA} or \textit{vanB} genes.\textsuperscript{5,6} In the Netherlands, 1%–2% of invasive \textit{E. faecium} isolates are VRE, and in Denmark, prevalence had risen to 11% by 2019, with particular predominance in the capital region.\textsuperscript{7,8} In both countries, infection control policies are in place to prevent nosocomial transmission of VRE (contact precautions for VRE carriers supplemented by contact tracing and augmented general hygiene measures during outbreaks),\textsuperscript{9,10} but not for ARE. Failure to control VRE transmission will most likely result in VRE endemicity due to replacement of nosocomial ARE populations by VRE.\textsuperscript{1,12}

Controlling VRE outbreaks imposes a great burden on finances and hospital personnel.\textsuperscript{13} To make an appropriate cost–benefit analysis of containing VRE spread in a healthcare system, it is essential to quantify the benefits of such a strategy. The most important threat for individual patients is the adversity patients experience due to VRE infection compared to ARE infection. A meta-analysis reported increased mortality after VRE bacteremia compared to ARE bacteremia,\textsuperscript{14} but most studies included had been performed before effective antibiotics for VRE were available. Since then, few have attempted to quantify the effects of VRE infection compared to ARE infection, and those available often suffered from methodological drawbacks, such as combining \textit{E. faecium} and \textit{E. faecalis} infection and incomplete control for confounding.\textsuperscript{15}

We investigated how much mortality is increased when vancomycin resistance is superimposed on ampicillin resistance in \textit{E. faecium} bacteremia in both the Netherlands and the capital region of Denmark. We also analyzed whether any such attributable mortality is the result of a delay in appropriate antibiotic therapy because this is the most likely mediating mechanism.

Methods

Study design, setting, and participants

We addressed a causal research question with an observational study in which confounding bias was dealt with using a 2-step approach. First, by means of matching, patients with ARE bacteremia and with underlying disease severity similar to the VRE bacteremia patients were chosen as comparison group. Second, we controlled for remaining imbalances in confounding factors after matching by means of adjustments in multivariable models.

This method resulted in a retrospective, matched-cohort study in which episodes of bacteremia caused by \textit{E. faecium} with co-resistance to ampicillin and vancomycin (designated VRE) were compared to control episodes of bacteremia caused by \textit{E. faecium} with resistance to ampicillin and susceptibility to vancomycin (designated ARE). Episodes with ampicillin-susceptible VRE bacteremias were excluded. Depending on the availability, a maximum of 4 ARE bacteremias were matched to each VRE bacteremia on 4 variables. Matched ARE bacteremias always originated from the same hospital and ward (categorized into 8 specialties). Subsequently, for matching length of hospital stay prior to bacteremia, the matching interval was determined such that from at least 5 ARE bacteremias (if available), patients could be selected with age most similar to the patient with VRE bacteremia (Supplementary Material online).

No formal sample size calculation was performed because, VRE bacteremias are rare in both countries, and we had to rely on the willingness of hospitals to participate. In the Netherlands, VRE bacteremia episodes were identified in 13 hospitals through the national surveillance system ISIS-AR\textsuperscript{15}; 11 participated in this study, as did 5 hospitals not linked to ISIS-AR (see Supplementary Table S1 online for details of participating hospitals). In Denmark, the DACOBAN database was used to identify patients with VRE bacteremia. DACOBAN is a registry of all positive blood cultures from 10 of 11 hospitals in the capital region.\textsuperscript{17} Patients with VRE bacteremia were identified in 4 of the 10 hospitals.

In the Netherlands, we included patients with VRE bacteremia that occurred between January 1, 2009, and December 31, 2012, with deviations in some hospitals (Supplementary Table S1 online). In Denmark, we included patients with VRE bacteremia that occurred between January 1, 2012, and December 31, 2014.

For resistance classification, ampicillin and vancomycin minimum inhibitory concentrations (MICs) or zone diameters were used as reported by local laboratories. All Danish laboratories interpreted antimicrobial susceptibility according to EUCAST standards, but most Dutch laboratories switched from CLSI to EUCAST standards around the study period.\textsuperscript{16} Vancomycin resistance had to be confirmed by E-test or demonstration of the presence of \textit{vanA} or \textit{vanB}. The specific VRE genotype was based on PCR-testing or on teicoplanin susceptibility (resistant categorized as \textit{vanA}, susceptible as \textit{vanB}) if PCR testing had not been performed.

The institutional review board of the coordinating center judged the study to be exempt from the Dutch Medical Research Involving Human Subjects Law due to its retrospective nature. Informed consent was not necessary because data were anonymized by treating physicians. In all participating study sites, local regulations for such studies were followed. In Denmark, the study was approved by the Danish Data Protection Agency (no. 2012-58-0004) and the Danish Health and Medicines Authority (no. 3-3013-1118/1).

Data collection

After selection of cases and controls, charts were reviewed with the date of the index blood culture (bacteremia onset) as the reference date. Follow-up data (censoring date or date of death) for at least 30 days after bacteremia onset, but preferably up to 1 year after bacteremia onset, were collected (Supplementary Material online). However, the primary outcome of the study was defined as mortality within 30 days of bacteremia onset. A description of the potential confounding variables, infection-related variables, and secondary outcomes for which data were collected is provided in the Supplementary Material (online). For Dutch patients, additional data were collected to calculate an Acute Physiology Score before bacteremia onset to better capture the prior state of health of patients aside from registered comorbidities.\textsuperscript{18}

Antibiotic use was registered from 30 days prior to bacteremia onset until 14 days after onset, including type of antibiotic, route of administration, and starting and stopping dates. Antibiotic use prior to bacteremia was considered a potential confounder, whereas treatment provided for the \textit{E. faecium} bacteremia episode was considered the main intermediate variable on the causal pathway leading from vancomycin resistance to increased mortality. To analyze this variable, on each calendar day from bacteremia onset onward (considered day 0), antibiotic therapy was categorized as (1) either \textit{E. faecium}-covering (ie, including vancomycin, linezolid, daptomycin, teicoplanin, quinupristin/dalfopristin and/or tigecycline, regardless of vancomycin resistance phenotype) or not,
and (2) appropriate (ie, all of the aforementioned antibiotics for ARE infection, all except vancomycin for vanB VRE infection, and all except vancomycin and teicoplanin for vanA VRE infection) or inappropriate.

**Statistical analysis**

The relation between ARE or VRE and 30-day mortality was estimated using Cox regression models, unadjusted as well as adjusted for potential confounding variables. All models were Cox proportional hazards models, with stratification on matched sets, robust standard errors, and correlation between individuals that were included multiple times. For models without censoring (ie, all except the model with 1 year follow-up), all episodes were given the same arbitrary follow-up time. The Efron approximation for tied survival times was used so that hazard ratios (HRs) could be interpreted as risk ratios (RRs). For the Dutch subgroup, an additional analysis was performed in which the variable Acute Physiology Score before bacteremia onset was added to a model already adjusted with regular confounders. All procedures are described in detail in the Supplementary Material (online). In case of missing values for the variables included in a model, individuals were excluded from the analysis.

Several additional models were created to evaluate mediation of the effect of VRE on mortality through appropriateness of antibiotic therapy. An interaction between vancomycin resistance and appropriateness of therapy was included. Because appropriateness of therapy is a time-varying variable, 3 models were created in which the baseline was moved to the end of day 0 (day of the index blood culture), +1, and +2, respectively. Patients having died or censored before or on the day of the baseline were removed from the analysis. Appropriateness of therapy in each model reflected the state at baseline. All statistical analyses were performed in R version 4.0.3 software (R Foundation for Statistical Computing, Vienna, Austria) using several packages.22–39

**Results**

**Patient characteristics**

Overall, 63 VRE episodes were matched with 234 ARE episodes: 36 and 130 for the Netherlands and 27 and 104 for Denmark. VRE and matched ARE bacteremia episodes had largely similar characteristics (Table 1). Differences between the 2 countries involved most prominently treatment restriction prior to bacteremia. The latter variable is generally registered on a dedicated location in Dutch health records but had to be extracted from written notes in Denmark. Also, comorbidities were retrieved from the DAcoban registry in Denmark, whereas they were extracted from medical notes in the Netherlands.

Most VRE were vanA (n = 41, 65%); 19 were vanB (30%); 1 isolate carried both vanA and vanB; and 2 isolates could not be categorized. All VRE isolates from Denmark (n = 27) were vanA. Also, 17 isolates were categorized based on teicoplanin susceptibility (3 vanA and 14 vanB, all from the Netherlands).

**Mortality**

Crude 30-day mortality rates were 40% for VRE and 32% for ARE: 33% and 27% for VRE and ARE, respectively, in the Netherlands and 48% and 38% in Denmark. In the Netherlands, the 30-day mortality rates per VRE phenotype were 29% for vanA and 37% for vanB. The unadjusted RR for 30-day mortality of VRE (compared to ARE) was 1.27 (95% confidence interval [CI], 0.87–1.84; Table 2). Adjustment for confounding increased the RR to 1.54 (95% CI, 1.06–2.25). Within the Dutch subgroup, addition of the confounder Acute Physiology Score before bacteremia onset to an otherwise optimized adjusted model reduced the RR of vancomycin resistance from 1.62 (95% CI, 0.85–3.12) to 1.17 (95% CI, 0.55–2.52) (Supplementary Table S3 online).

Moreover, 1-year mortality appeared to be higher among Danish patients with VRE compared to patients with ARE bacteremia or Dutch patients with VRE or ARE bacteremia, although confidence intervals (CIs) of survival curves were largely overlapping (Fig. 1). In the Cox model for mortality up to 1 year, the adjusted HR for VRE amounted to 1.25 (95% CI, 0.80–1.98).

**Antibiotic therapy**

Visual inspection of cumulative incidence plots revealed that initiation of E. faecium-covering antibiotic therapy occurred faster in VRE than in ARE episodes (Fig. 2) but that initiation of appropriate antibiotic therapy occurred faster for ARE compared to VRE bacteremia (Fig. 3). In Denmark, appropriate antibiotic therapy for both ARE and VRE bacteremia was started earlier than in the Netherlands, and VRE treatment often consisted of combination treatment with linezolid and daptomycin (Table 3).

Inappropriate antibiotic therapy on the day of the index blood culture (day 0) is a potential mediator of an increase in mortality in VRE cases, but inclusion of this variable in the model relating VRE to 30-day mortality did not reduce the point estimate of VRE (Table 2). In models with an interaction between vancomycin resistance and appropriateness of therapy, VRE patients on inappropriate therapy consistently fared worse than ARE patients on inappropriate therapy (Table 4). The effect estimates for both ARE and VRE patients on appropriate therapy were uncertain.

**Discussion**

The results of this study reveal that, after matching and further analytic control for confounders, VRE bacteremia was, compared to ARE bacteremia, associated with 54% higher risk for mortality after 30 days (RR, 1.54; 95% CI, 1.06–2.25). However, this increased risk of death must be explained by other factors than a delay in appropriate antibiotic therapy.

Our estimate for the effect of VRE on mortality is similar to the reported pooled OR of 2.52 (95% CI, 1.9–3.4) in a meta-analysis from 2005, which translates to an RR of 1.70 with a 32% mortality rate in the nonexposed group. This seems remarkably identical; the studies included in that meta-analysis had been performed before the availability of effective antibiotics for VRE, such as linezolid and daptomycin. However, a small study comparing older and newer antibiotics in 113 VRE bacteremia cases concluded that newer antibiotics had not brought discernible benefits to patient outcome. A later meta-analysis on the effect of VRE on mortality in the era of effective antibiotic therapy could only present an unadjusted estimate and thus could not be compared to our study. Recent Australian and German studies all found point estimates reflecting increased mortality in case of vancomycin resistance, with confidence intervals indicating nonsignificance. By analyzing the E. faecium bacteremia subset and not including intermediate variables in the adjusted model, the OR of 1.283
The most closely reflects our estimation procedure. There are 3 causal pathways along which vancomycin resistance could lead to increased mortality: (1) increased virulence of VRE compared to ARE, (2) less effective or more toxic antibiotics for VRE than for ARE, and (3) a delay in initiation of appropriate antibiotic therapy for VRE bacteremia. We cannot fully exclude a systematic difference in pathogenicity between ARE and VRE. For example, Bender et al. showed that acquisition of vanB by E. faecium is accompanied by the transfer of larger genetic fragments. However, most studies conclude that both phenotypes belong to the same, well-characterized, core genomic lineage of E. faecium.

Regarding the comparative intrinsic effectiveness of the antibiotic options for VRE, the data are limited. In studies on gram-positive infections including bacteremia in general and on methicillin-resistant Staphylococcus aureus (MRSA) infection specifically, linezolid and daptomycin have performed on par with

---

**Table 1.** Characteristics and Outcomes of Vancomycin-Resistant *Enterococcus faecium* (VRE) and Matched Ampicillin-Resistant *E. faecium* (ARE) Bacteremias*

| Characteristic                                      | Netherlands ARE Bacteremia | VRE Bacteremia | Denmark ARE Bacteremia | VRE Bacteremia |
|-----------------------------------------------------|---------------------------|---------------|-----------------------|---------------|
| **Potential confounding variables**                 |                           |               |                       |               |
| Sex, female, no./total (%)                          | 47/130 (36)               | 19/36 (53)    | 51/104 (49)           | 10/27 (37)    |
| Age, median (IQR)                                   | 70 (62–76)                | 69 (62–76)    | 69 (63–77)            | 71 (58–76)    |
| Hospital ward at bacteremia onset, no./total (%)    | 47/130 (36)               | 15/36 (42)    | 31/104 (30)           | 8/27 (30)     |
| Internal medicine                                   | 47/130 (36)               | 15/36 (42)    | 31/104 (30)           | 8/27 (30)     |
| ICU                                                 | 48/130 (37)               | 11/36 (31)    | 25/104 (24)           | 6/27 (22)     |
| Gastroenterology/surgery                            | 34/130 (26)               | 9/36 (25)     | 31/104 (30)           | 8/27 (30)     |
| Other                                               | 1/130 (1)                 | 1/36 (3)      | 17/104 (16)           | 5/27 (19)     |
| **Bacteremia origin, no./total (%)**                |                           |               |                       |               |
| Hospital onset                                      | 113/130 (87)              | 29/36 (81)    | 93/104 (89)           | 24/27 (89)    |
| Healthcare associated                               | 15/130 (12)               | 4/36 (11)     | 10/104 (10)           | 1/27 (4)      |
| Community onset                                     | 2/130 (2)                 | 3/36 (8)      | 1/104 (1)             | 1/27 (4)      |
| Length of hospital stay prior to bacteremia, median d (IQR) | 17 (11–24)              | 20 (14–36)    | 18 (6–24)             | 21 (10–29)    |
| Charlson index, median (IQR)                        | 2 (2–3)                   | 2 (1–4)       | 3 (1–4)               | 3 (2–6)       |
| Neutropenia at bacteremia onset, no./total (%)      | 32/130 (25)               | 11/36 (31)    | 8/104 (8)             | 6/27 (22)     |
| Treatment restriction in place at bacteremia onset, no./total (%) | 26/130 (20)              | 10/36 (28)    | 5/102 (5)             | 2/27 (7)      |
| Surgical procedure within 30 d prior to bacteremia, no./total (%) | 46/130 (35)              | 9/36 (25)     | 33/103 (32)           | 12/27 (44)    |
| Known colonization with *E. faecium*, no./total (%) |                           |               |                       |               |
| No                                                  | 90/130 (69)               | 18/36 (50)    | 88/104 (85)           | 16/27 (59)    |
| Yes, ARE                                            | 38/130 (29)               | 7/36 (19)     | 16/104 (15)           | 2/27 (7)      |
| Yes, VRE                                           | 2/130 (2)                 | 11/36 (31)    | 0/104 (0)             | 9/27 (33)     |
| Antibiotic use within 30 d prior to bacteremia, no./total (%) | 122/130 (94)             | 33/36 (92)    | 95/104 (91)           | 25/27 (93)    |
| Vancomycin use within 30 d prior to bacteremia, no./total (%) | 13/130 (10)              | 15/36 (42)    | 9/104 (9)             | 6/27 (22)     |
| **Infection-related variables**                     |                           |               |                       |               |
| Polymicrobial bacteremia, no./total (%)             | 35/130 (27)               | 8/36 (22)     | 31/103 (30)           | 11/27 (41)    |
| Severe sepsis at bacteremia onset, no./total (%)    | 30/129 (23)               | 10/36 (28)    | 20/104 (19)           | 4/27 (15)     |
| Bacteremia source, no./total (%)                    |                           |               |                       |               |
| Primary bacteremia/central line infection/not identifiable from medical file | 60/130 (46)              | 19/36 (53)    | 59/104 (57)           | 11/27 (41)    |
| Biliary tract infection                             | 15/130 (12)               | 4/36 (11)     | 10/104 (10)           | 2/27 (7)      |
| Other intra-abdominal infection                     | 35/130 (27)               | 9/36 (25)     | 12/104 (12)           | 7/27 (26)     |
| Other                                               | 20/130 (15)               | 4/36 (11)     | 23/104 (22)           | 7/27 (26)     |
| **Outcome variables**                               |                           |               |                       |               |
| Length of hospital stay after bacteremia onset, median d (IQR) | 22 (10–38)               | 13 (8–24)     | 16 (8–36)             | 14 (6–30)     |
| Thirty-day mortality, no./total (%)                 | 35/130 (27)               | 12/36 (33)    | 40/104 (38)           | 13/27 (48)    |

Note. ICU, intensive care unit; IQR, interquartile range.

*This table presents a selection of recorded variables. A full overview is available in Supplementary Table S2 (online).
However, whether even high-dose daptomycin (10–12 mg/kg/day) achieves drug exposure levels to reliably treat enterococcal infections remains uncertain. In this study, daptomycin for VRE bacteremia (dose, 6 mg/kg/day) was consistently prescribed in combination with linezolid. The observed increased mortality in cases of VRE bacteremia, therefore, could be expected to result from a delay in appropriate antibiotic therapy, which has been implicated previously in worse outcomes in cases of enterococcal bacteremia. Our models that included appropriateness of therapy would have lent support to this hypothesis if mortality risk had no longer depended on the presence of vancomycin resistance after stratification on appropriateness of therapy. Instead, VRE patients on inappropriate therapy continuously fared worse than ARE patients on inappropriate therapy. Importantly, therapy over time may be reflective of the evolving disease severity of the patient, and collider bias may be induced by conditioning on appropriateness of therapy. Thus, the effect estimates of appropriateness of therapy after baseline may not reflect true causal associations. However, this trend is discernible from the day of the index blood culture onward, which increases our confidence that the difference in duration until appropriate therapy is unable to explain the increased mortality in case of VRE bacteremia. A final indication for this hypothesis stems from the comparison between countries in this study. Overall mortality in Denmark for both ARE and VRE bacteremia was higher than in the Netherlands, although appropriate therapy for both types of bacteremia was initiated considerably faster in Denmark than in the Netherlands.

| Characteristic                                      | Combined Unadjusted Models | Denmark Unadjusted Models | Combined Adjusted Models | Main Analysis | Therapy Added |
|-----------------------------------------------------|----------------------------|---------------------------|--------------------------|---------------|---------------|
| No. of patients analyzed                            | 297                        | 166                       | 131                      | 297           | 297           |
| No. of deaths                                       | 100                        | 47                        | 53                       | 100           | 100           |
| Vancomycin resistance                               | 1.27 (0.87–1.84)           | 1.16 (0.65–2.06)          | 1.37 (0.84–2.25)         | 1.54 (1.06–2.25) | 1.55 (1.07–2.26) |
| Inappropriate antibiotic therapy on day of index blood culture | 2.79 (0.99–7.86)          |                           |                          |               |               |
| Solid malignancy                                    | 2.28 (1.47–3.53)           | 2.28 (1.46–3.55)          |                          |               |               |
| Diabetes mellitus                                   | 1.81 (1.11–2.96)           | 1.97 (1.19–3.27)          |                          |               |               |
| Cerebrovascular disease                             | 0.37 (0.16–0.83)           | 0.39 (0.18–0.85)          |                          |               |               |
| Mechanical ventilation at bacteremia onset          | 3.44 (1.46–8.12)           | 3.68 (1.59–8.49)          |                          |               |               |

This table presents risk ratios (RR, with 95% confidence intervals) for 30-day mortality for the exposure of interest (vancomycin resistance), with and without adjustment for confounding variables, and with and without the intermediate variable inappropriate antibiotic therapy on the day of the index blood culture. In the Supplementary Material (online), the adjustment procedure is described. Combined models include data from both the Netherlands and Denmark.
These biologically plausible mediators cannot explain increased mortality due to vancomycin resistance; thus, the possibility remains that these observed effects are due to unmeasured confounding. This possibility is supported by 2 additional observations. First, a measure for clinical disease severity immediately before bacteremia onset was not available for the Danish patients. For the Dutch patients, we could calculate the Acute Physiology Score, and when included in our country-specific analyses, it substantially reduced the effect estimate for mortality. Second, the association between vancomycin resistance and mortality persisted over the course of a full year. Infections may have long-term sequelae, but it seems unlikely that sustained mortality differences will emerge that can be causally related to vancomycin resistance. A Dutch population-based study reported that the incidence of recurrent bacteremia, an example of a long-term consequence, only marginally differed between ARE and VRE bacteremias. An alternative explanation is that underlying prognostic factors at the time of onset of enterococcal bacteremia were dissimilar.

This study has several limitations. First, results of this study may not apply to E. faecium bacteremia in general because a nonrandom subset of ARE bacteremias was included. The matched design does not allow direct comparisons of raw proportions other than for VRE versus ARE. Second, some loss in precision may be expected in stratified analyses because not all matched sets can be used for parameter estimation. Third, measurements of comorbidities and treatment restrictions differed between both countries, whereas these differences were not included in models. Fourth, duration until initiation of appropriate antibiotic therapy could not be reliably measured in hours and was reflected instead by calendar days.

Finally, some studies suggest that the incidence of infections with VRE occur on top of the existing incidence of infections caused by vancomycin-susceptible enterococci. In that case, a comparison between VRE bacteremia and an uninfected control group would be more appropriate, as described by Chiang et al. Notably, however, these incidence rates may have been confounded by the fact that E. faecalis was not separated from E. faecium, and results from molecular epidemiological studies provided

---

**Fig. 2.** Cumulative incidence plots showing time to Enterococcus faecium–covering antibiotic therapy (Efm Tx), and its competing risk ‘mortality before onset of Efm Tx’, separately for vancomycin-resistant E. faecium (VRE) and matched ampicillin-resistant E. faecium (ARE) bacteremias.

**Fig. 3.** Cumulative incidence plots showing time to appropriate antibiotic therapy (appr Tx), and its competing risk ‘mortality before onset of appr Tx’, separately for vancomycin-resistant Enterococcus faecium (VRE) and matched ampicillin-resistant E. faecium (ARE) bacteremias.
Table 3. Overview of Antibiotic Therapy for Vancomycin-Resistant Enterococcus faecium (VRE) and Matched Ampicillin-Resistant E. faecium (ARE) Bacteremias

| Characteristic                          | ARE          | VRE          |
|----------------------------------------|--------------|--------------|
|                                        | End of Day 0, No. (%)* | End of Day +3, No. (%)* |
|                                        | NL (n = 130) | DK (n = 104) | NL (n = 36) | DK (n = 27) | NL (n = 130) | DK (n = 104) | NL (n = 36) | DK (n = 27) |
| Deceased                               | 1 (1)        | 2 (2)        | 1 (3)       | 1 (4)       | 12 (9)       | 13 (12)      | 4 (11)      | 4 (15)      |
| Censoredb                              |              |              |             |             | 1 (1)        |              |             |             |
| Discharged                              | 1 (1)        |              | 1 (4)       |             | (4)          | 1 (1)        | 1 (3)       | 2 (7)       |
| Data on antibiotic therapy available    | 129          | 102          | 35          | 26          | 117          | 91           | 32          | 23          |
| E. faecium-covering antibiotic therapy  | 10 (8)       | 5 (5)        | 13 (37)     | 7 (27)      | 76 (65)      | 82 (90)      | 20 (62)     | 22 (96)     |
| Vancomycin iv                          | 9 (7)        | 5 (5)        | 12 (34)     | 5 (19)      | 72 (62)      | 79 (87)      | 8 (25)      | 2 (9)       |
| Linezolid iv                           | 1 (3)        | 1 (4)        |             |             | 1 (1)        | 1 (1)        | 6 (19)      | 7 (30)      |
| Daptomycin iv + linezolid iv           |              |              |             |             |              |              |             |             |
| Teicoplanin iv                         | 1 (1)        |              | 2 (2)       | 4 (12)      |              |              |             |             |
| Linezolid po                           | 1 (4)        |              |             |             |              |              |             |             |
| Daptomycin iv                          |              |              |             |             | 2 (2)        |              |             |             |
| Vancomycin intrathecally               |              |              |             |             | 1 (1)        |              |             |             |
| Linezolid iv + tigecycline iv          |              |              |             |             |              |              |             |             |
| Appropriate antibiotic therapy         | 10 (8)       | 5 (5)        | 1 (3)       | 2 (8)       | 76 (65)      | 82 (90)      | 12 (38)     | 20 (87)     |
| Appropriate antibiotic therapy or      |              |              |             |             |              |              |             |             |
| central line removed                   |              |              |             |             |              |              |             |             |

Note. ARE, ampicillin-resistant Enterococcus faecium bacteremia; VRE, vancomycin-resistant Enterococcus faecium bacteremia; NL, Netherlands; po, orally.

bDay 0 is the day of the index blood culture of the ARE/VRE bacteremia episode.

Table 4. Regression Models for 30-Day Mortality Evaluating Appropriateness of Antibiotic Therapy

| Characteristic                          | Baseline After Day |
|----------------------------------------|--------------------|
|                                        | 0                  | +1                 | +2                 |
|                                        | No. of patients analyzed | 289 | 283 | 274 |
|                                        | No. of deaths       | 95   | 88  | 80  |
| ARE on inappropriate therapy          | Reference           | Reference           | Reference           |
| ARE on appropriate therapy            | 0.41 (0.10–1.74)    | 0.82 (0.45–1.51)    | 1.01 (0.57–1.79)    |
| VRE on inappropriate therapy         | 1.24 (0.82–1.85)    | 1.15 (0.71–1.88)    | 1.40 (0.73–2.70)    |
| VRE on appropriate therapy           | NA                 | 1.53 (0.68–3.46)    | 1.32 (0.64–2.71)    |
| Adjusted Models                       | No. of patients analyzed | 289 | 276 | 268 |
|                                        | No. of deaths       | 95   | 87  | 80  |
| ARE on inappropriate therapy          | Reference           | Reference           | Reference           |
| ARE on appropriate therapy            | 0.33 (0.08–1.40)    | 0.79 (0.43–1.45)    | 0.82 (0.47–1.43)    |
| VRE on inappropriate therapy         | 1.69 (1.09–2.61)    | 2.01 (1.13–3.57)    | 2.43 (0.94–6.33)    |
| VRE on appropriate therapy           | NA                 | 5.79 (1.43–23.40)   | 1.73 (0.83–3.61)    |

Note. ARE, ampicillin-resistant Enterococcus faecium bacteremia; VRE, vancomycin-resistant Enterococcus faecium bacteremia; NA, not available.

*This table presents risk ratios (RR, with 95% confidence intervals) for 30-day mortality for the interaction between vancomycin resistance and appropriateness of therapy. The baseline for these models (at which appropriateness of antibiotic therapy is assessed each time) is positioned on 3 different moments, namely the end of the day of the index blood culture (day 0), the end of the day after (day +1), and the end of the day thereafter (day +2). RRs are presented with and without adjustment for confounding variables. In the Supplementary Material (online), the adjustment procedure is described. All models include data from both the Netherlands and Denmark.
strong evidence that ARE and VRE occupy the same niche within the bacterial hospital ecology.3

In conclusion, VRE bacteremia was, when compared to ARE bacteremia, associated with higher mortality. This finding could not be explained by delays in initiation of appropriate antibiotic therapy, although the relevant models may be affected by collider bias, post hoc detection of spurious associations, and simultaneous lack of statistical power for some subgroups. One possible explanation for the higher mortality is unmeasured confounding. An alternative explanation is that VRE is more virulent than ARE, for which the genetic basis would then most likely be encoded in the accessory genome. Further studies are warranted to explore this possibility.

Acknowledgments. We thank all participating hospitals for making data collection possible. We specifically thank Marja Smid for her assistance with the data collection in the Netherlands, and Kim Gradell and Steen Rasmussen for extraction of comorbidity data in Denmark. We also thank Rob Willems for critically reviewing an earlier version of this manuscript.

Financial support. This work was supported by a research grant from the Netherlands Organisation for Health Research and Development (project no. 205200007).

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

Supplementary material. To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2021.216

References

1. Top J, Willems RIL, Bonten MJM. Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen. FEMS Immunol Med Microbiol 2008;52:297–308.

2. Surveillance atlas of infectious diseases. European Centre for Disease Prevention and Control website. https://atlas.ecdc.europa.eu/public/index.aspx. Accessed March 27, 2021.

3. de Greeff SC, Mouton JW. NethMap 2017: Consumption of Antimicrobial Agents and Antimicrobial Resistance among Medically Important Bacteria in the Netherlands in 2016. Stichting Werkgroep Antibioticabeleid & Rijksinstituut voor Volkgezondheid en Milie; 2017.

4. Borck Hag B, Korsgaard H, Sonksen UW. DANMAP 2016: Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Food and Humans in Denmark. Statens Serum Institut, DTU Veterinærinstituttet & DTU Fødevareinstituttet; 2017.

5. Guzman Prieto AM, van Schaik W, Rogers MRC, et al. Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones? Front Microbiol 2016;7:788.

6. Howden BP, Holt KE, Lam MMC, et al. Genomic insights to control of vancomycin-resistant enterococci. MBio 2013;4(4):e00412–13.

7. Pinfold M, Gumpert H, Bayliss S, et al. Genomic analysis of 495 vancomycin-resistant Enterococcus faecium reveals broad dissemination of a vanA plasmid in more than 19 clones from Copenhagen, Denmark. J Antimicrob Chemother 2017;72:40–47.

8. Raven KE, Reuter S, Reynolds R, et al. A decade of genomic history for healthcare-associated Enterococcus faecium in the United Kingdom and Ireland. Genome Res 2016;26:1388–1396.

9. Hammerum AM, Baig S, Kamel Y, et al. Emergence of vanA Enterococcus faecium in Denmark, 2005–2015. J Antimicrob Chemother 2017;72:2184–2190.

10. Bijzonder Resisteante Micro-Organismen (BRMO). Werkgroep Infectiepreventie; 2013.

11. Nationale Infectievoorkenningsbeurs 2011 Met Supplerende Forholdsregler Ved Infektion Og Bærertilstand i Sundhedsektoren (S. Udgaard). Central Enhed for Infektionhygiejne (Statens Serum Institut); 2016.

12. Johnstone J, Pollicario ME, Lam F, et al. Rates of blood cultures positive for vancomycin-resistant Enterococcus in Ontario: a quasi-experimental study. CMAJ Open 2017;5:E273–E280.

13. Dik JWH, Dinkelaeker AG, Vemer P, et al. Cost-analysis of seven nosocomial outbreaks in an academic hospital. PLoS One 2016;11:e0149226.

14. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327–333.

15. Premature C, MacDougall C, Johnston J, et al. VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2016;37:26–35.

16. Altorf-van der Kuil W, Schoffelen AF, de Greeff SC, et al. National laboratory-based surveillance system for antimicrobial resistance: a successful tool to support the control of antimicrobial resistance in the Netherlands. Eurosurveillance 2017;22(46):pii=17-00062.

17. Gradell KO, Schönheyder HC, Arpi M, Knudsen JD, Östergaard C, Søgaard M. The Danish Collaborative Bacteremia Network (DACOBAN) database. Clin Epidemiol 2014;6:301–308.

18. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalised adults. Chest 1991;100:1619–1636.

19. Cummings P. Re: “Estimating the relative risk in cohort studies and clinical trials of common outcomes.” Am J Epidemiol 2004;159:213.

20. Greenland S, Daniel R, Pearce N. Outcome modelling strategies in epidemiology: traditional methods and basic alternatives. Int J Epidemiol 2016;45:565–575.

21. R Core Team. R: A Language and Environment for Statistical Computing: Vienna, Austria: R Foundation for Statistical Computing; 2020.

22. Therneau T. A package for survival analysis in R (R package version 3.2-7). https://CRAN.R-project.org/package=survival. Published online 2020. Accessed May 15, 2021.

23. Gray B. cmpsk: subdistribution analysis of competing risks (R package version 2.2–10). https://cran.r-project.org/web/packages/cmpsk/cmpsk.pdf. Published online 2020. Accessed May 15, 2021.

24. Harrell Jr FE. rms: regression modeling strategies (R package version 6.0–1). https://cran.r-project.org/web/packages/rms/index.html. Published online 2020. Accessed May 15, 2021.

25. Buuren S van, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R (R package version 1.0.2). https://cran.r-project.org/web/packages/mice/mice.pdf. Published online 2020. Accessed May 15, 2021.

26. Dahl DB, Scott D, Roosen C, Magnusson A, Swinton J. sttable: export tables in an elegant way (R package version 2.2-10). https://cran.r-project.org/web/packages/sttable/sttable.pdf. Published online 2020. Accessed May 15, 2021.

27. Cheah ALY, Spelman T, Liew D, et al. Comparison of mortality, length of stay and costs of hospitalization in patients with vancomycin-resistant Enterococcus bacteremia: a cohort study including over 1,000 cases of enterococcal bloodstream infection. CMAJ Open 2013;19:E181–E189.

28. Kramer TS, Remschmidt C, Werner S, et al. The APACHE III prognostic model: a reevaluation of its performance in a cohort of low-risk patients who underwent elective total hip or knee replacement surgery. Chest 2017;151:1635–1636.

29. Knaus WA, Wang L, Draper EA, et al. The APACHE III prognostic system: a model for outcome estimation in intensive care units. Crit Care Med 1991;19:767–775.

30. Knaus WA, Wang L, Draper EA, et al. The APACHE III prognostic system: a model for outcome estimation in intensive care units. Crit Care Med 1991;19:767–775.

31. Coelho LF, de Andrade AA, da Silva JS, et al. Evaluation of the model Acute Physiology and Chronic Health Evaluation II (APACHE II) in a cohort of 218 septic patients: a prospective study. Intensive Care Med 2010;36:1739–1745.

32. Cheah ALY, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect 2016;37:1155–1162.

33. Kramer TS, Remschmidt C, Werner S, et al. The APACHE III prognostic model: a reevaluation of its performance in a cohort of low-risk patients who underwent elective total hip or knee replacement surgery. Chest 2017;151:1635–1636.

34. Dubler S, Lenz M, Zimmermann S, et al. Does vancomycin resistance increase mortality in Enterococcus faecium bacteremia after orthotopic liver transplantation? A retrospective study. Antimicrob Resist Infect Control 2020;9:22.

Downloaded from https://www.cambridge.org/core. 29 Jun 2021 at 04:53:44, subject to the Cambridge Core terms of use.
35. Bender JK, Kalmbach A, Fleige C, Klare I, Fuchs S, Werner G. Population structure and acquisition of the vanB resistance determinant in German clinical isolates of Enterococcus faecium ST192. Sci Rep 2016;6:21847.
36. Sparham SJ, Howden BP. Linezolid. In: Grayson ML, Cosgrove SE, Crowe S, et al, editors. Kucers’ the Use of Antibiotics: A Clinical Review of Antimicrobial, Antifungal, Antiparasitic, and Antiviral Drugs, 7th ed. Milton Park, UK: Taylor & Francis Group; 2017:1293–1347.
37. Muller AE, Gyssens IC. Daptomycin. In: Grayson ML, Cosgrove SE, Crowe S, et al, editors. Kucers’ the Use of Antibiotics: A Clinical Review of Antimicrobial, Antifungal, Antiparasitic, and Antiviral Drugs, 7th ed. Milton Park, UK: Taylor & Francis Group; 2017:866-907.
38. Turnidge J, Kahlmeter G, Cantón R, MacGowan A, Giske CG, European Committee on Antimicrobial Susceptibility Testing, Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. Clin Microbiol Infect 2020;26:1039–1043.
39. Zasowski EJ, Claey K, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis 2016; 62:1242–1250.
40. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615–625.
41. Leibovici L. Long-term consequences of severe infections. Clin Microbiol Infect 2013;19:510–512.
42. Woudt SHS, de Greeff SC, Schoffelen AF, Vlek ALM, Bonten MJM, Infectious Diseases Surveillance Information System–Antimicrobial Resistance (ISIS-AR) Study Group. Antibiotic resistance and the risk of recurrent bacteremia. Clin Infect Dis 2018;66:1651–1657.
43. Ammerlaan HSM, Harbarth S, Buting AGM, et al. SECular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 2013;56:798–805.
44. Popiel KY, Miller MA. Evaluation of vancomycin-resistant enterococci (VRE)-associated morbidity following relaxation of VRE screening and isolation precautions in a tertiary care hospital. Infect Control Hosp Epidemiol 2014;35:818–825.
45. Chiang H-Y, Perencevich EN, Nair R, et al. Incidence and outcomes associated with infections caused by vancomycin-resistant enterococci in the United States: systematic literature review and meta-analysis. Infect Control Hosp Epidemiol 2017;38:203–215.